Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Cardiology Reports
Published in: Current Cardiology Reports 10/2015

01-10-2015 | Psychological Aspects of Cardiovascular Diseases (A Steptoe, Section Editor)

Management of Depression After Myocardial Infarction

Author: Peter A. Shapiro

Published in: Current Cardiology Reports | Issue 10/2015

Login to get access

Abstract

Depression in patients who have had a myocardial infarction is an important clinical problem because it is extremely common and because the comorbidity complicates depression treatment and worsens the cardiovascular prognosis. Studies of psychotherapy, exercise, pharmacotherapy, and collaborative care demonstrate that effective treatment of depression is possible but the strength of the effects seen in most studies is low, and cardiovascular and all-cause morbidity and mortality benefits have not been proven. Recent collaborative care studies have had promising outcomes. For pharmacotherapy, side effects, including bleeding and arrhythmia risks, require special attention. Recovery from depression is associated with better long-term cardiovascular prognosis, while treatment per se is not.
Literature
1.•
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–e322. This annual update from the American Heart Association provides a wealth of useful material.CrossRefPubMed
2.
Centers for Disease Control and Prevention. Million hearts: strategies to reduce the prevalence of leading cardiovascular disease risk factors—United States, 2011. MMWR. 2011;60:1248–51.
3.
España-Romero V, Artero EG, Lee D-C, Sui X, Baruth M, Ruiz JR, et al. A prospective study of ideal cardiovascular health and depressive symptoms. Psychosomatics. 2013;54:525–35.CrossRefPubMed
4.
Doyle F, Rohde D, Rutkowska A, Morgan K, Cousins G, McGee H. Systematic review and meta-analysis of the impact of depression on subsequent smoking cessation in patients with coronary heart disease: 1990 to 2013. Psychosom Med. 2015;76:44–57.CrossRef
5.
Riegel B, Lee CS, Dickson VV. Self-care in patients with chronic heart failure. Nat Rev Cardiol. 2011;8:644–54.CrossRefPubMed
6.
Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med. 2004;66:802–13.CrossRefPubMed
7.
van Melle JP, de Jonge P, Spijkerman TA, Tijssen JGP, Ormel J, van Veldhuisen DJ, et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med. 2004;66:814–22.CrossRefPubMed
8.
Thombs BD, Bass EB, Ford DE, Stewart KJ, Tsilidis KK, Patel U, et al. Prevalence of depression in survivors of acute myocardial infarction. Review of the evidence. J Gen Intern Med. 2006;21:30–8.PubMedCentralCrossRefPubMed
9.
Doyle F, McGee H, Conroy R, Conradi HJ, Meijer A, Steeds R, et al. Systematic review and individual patient data meta-analysis of sex differences in depression and prognosis in persons with myocardial infarction: a MINDMAPS study. Psychosom Med. 2015;77:419–28.CrossRefPubMed
10.
Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J. 2006;27:2763–74.CrossRefPubMed
11.
Meijer A, Conradi HJ, Bos EH, Anselmino M, Carney RM, Denollet J, et al. Adjusted prognostic association of depression following myocardial infarction with mortality and cardiovascular events: individual patient data meta-analysis. Br J Psychiatry. 2013;203(2):90–102. doi:10.​1192/​bjp.​bp.​112.​111195.CrossRefPubMed
12.••
Lichtman JH, Froelicher ES, Blumenthal JA, Carney RM, Doering LV, Frasure-Smith N, et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation. 2014;129:1350–69. This is an authoritative review of depression as a risk factor for recurrent cardiovascular events and mortality in patients with acute coronary events.CrossRefPubMed
13.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington VA: American Psychiatric Association; 2013.
14.
Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002;288:351–7.CrossRefPubMed
15.
Lichtman JH, Bigger Jr JT, Blumenthal JA, Frasure-Smith N, Kaufmann PG, Lesperance F, et al. Depression and coronary heart disease. Recommendations for screening, referral, and treatment. A science advisory from the American Heart Association prevention committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research. Circulation. 2008;118:1768–75.CrossRefPubMed
16.
Kroenke K, Spitzer RL, Williams JBW. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41:1284–92.CrossRefPubMed
17.
18.
19.
Glassman AH, O’Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JTJ, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288:701–9.CrossRefPubMed
20.
Glassman AH, Bigger JTJ, Gaffney M, Shapiro PA, Swenson JR. Onset of major depression associated with acute coronary syndromes. Relationship of onset, major depressive disorder history, and episode severity to sertraline benefit. Arch Gen Psychiatry. 2006;63:283–8.CrossRefPubMed
21.••
Davidson KW, Rieckmann N, Clemow L, Schwartz JE, Shimbo D, Medina V, et al. Enhanced depression care for patients with acute coronary syndrome and persistent depressive symptoms: coronary psychosocial evaluation studies randomized controlled trial. Arch Intern Med. 2010;170:600–8. This is the first study demonstrating the value of implementation of the collaborative care IMPACT model in post-MI patients.PubMedCentralCrossRefPubMed
22.
Writing Committee for the ENRICHD Investigators. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) randomized trial. JAMA. 2003;289:3106–16.CrossRef
23.
Carney RM, Blumenthal JA, Freedland KE, Youngblood M, Veith RC, Burg MM, et al. Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) Study. Psychosom Med. 2004;66:466–74.CrossRefPubMed
24.
Unutzer J, Katon W, Callahan CM, Williams Jr JW, Hunkeler E, Harpole L, et al. Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA. 2002;288:2836–45.CrossRefPubMed
25.
Klerman GL, Weissman MM, Rounsaville BJ, Chevron ES. Interpersonal psychotherapy of depression. New York: Basic Books; 1984.
26.
Lesperance F, Frasure-Smith N, Koszycki D, Laliberte M-A, van Zyl LT, Baker B, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA. 2007;297:367–79.CrossRefPubMed
27.
Welton NJ, Caldwell DM, Adamopoulos E, Vedhara K. Mixed treatment comparison meta-analysis of complex interventions: psychological interventions in coronary heart disease. Am J Epidemiol. 2009;169(9):1158–65.CrossRefPubMed
28.
Whalley B, Rees K, Davies P, Bennett P, Ebrahim S, Liu Z, West R, Moxham T, Thompson David R, Taylor Rod S. Psychological interventions for coronary heart disease. Cochrane Database Syst Rev [serial on the Internet]. 2011;(8):CD002902. doi:10.​1002/​14651858.​CD002902.​pub3.
29.
Dickens C, Cherrington A, Adeyemi I, Roughley K, Bower P, Garrett C, et al. Characteristics of psychological interventions that improve depression in people with coronary heart disease: a systematic review and meta-regression. Psychosom Med. 2013;75:211–21.CrossRefPubMed
30.
Rutledge T, Redwine LS, Linke SE, Mills PJ. A meta-analysis of mental health treatments and cardiac rehabilitation for improving clinical outcomes and depression among patients with coronary heart disease. Psychosom Med. 2013;75:335–49.CrossRefPubMed
31.••
Blumenthal JA, Sherwood A, Babyak MA, Watkins LL, Smith PJ, Hoffman BM, et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results From the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. J Am Coll Cardiol. 2012;60:1053–63. This study dramatically illustrates the value of sustained aerobic exercise therapy for depression in patients with coronary disease.PubMedCentralCrossRefPubMed
32.••
Blumenthal J, Babyak MA, O’Connor C, Keteyian S, Landzberg J, Howlett J, et al. Effects of exercise training on depressive symptoms in patients with chronic heart failure: the HF-Action randomized trial. JAMA. 2012;308:465–74. This study demonstrates both a survival benefit and a depression benefit of exercise for depressed patients with CHF.PubMedCentralPubMed
33.
Strik JJMH, Honig A, Lousberg R, Lousberg AHP, Cheriex EC, Tuynman-Qua HG, et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosom Med. 2000;62:783–9.CrossRefPubMed
34.
Glassman AH, Bigger Jr JT, Gaffney M. Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression: seven-year follow-up of SADHART participants. Arch Gen Psychiatry. 2009;66:1022–9.CrossRefPubMed
35.
McFarlane A, Kamath MV, Fallen EL, Malcolm V, Cherian F, Norman G. Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. Am Heart J. 2001;142:617–23.CrossRefPubMed
36.
Mohapatra P, Kar N, Kar G, Behera M. Effectiveness of sertraline in treatment of depression in a consecutive sample of patients with acute myocardial infarction: six month prospective study on outcome. Clin Pract Epidemiol Ment Health. 2005;1:26.PubMedCentralCrossRefPubMed
37.
Michalakeas CA, Parissis JT, Douzenis A, Nikolaou M, Varounis C, Andreadou I, et al. Effects of sertraline on circulating markers of oxidative stress in depressed patients with chronic heart failure: a pilot study. J Card Fail. 2011;17:748–54.CrossRefPubMed
38.
O’Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, et al. Safety and efficacy of sertraline for depression in patients with heart failure results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol. 2010;56:692–9.PubMedCentralCrossRefPubMed
39.
van Zyl LT, Lesperance F, Frasure-Smith N, Malinin AI, Atar D, Laliberte MA, et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study. J Thromb Thrombolysis. 2009;27:48–56.CrossRefPubMed
40.•
Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ. 2013;346:f288. This study provides a useful picture of the correlation of antidepressant dose with QT interval for many antidepressants and illustrates that citalopram has the steepest dose–response relationship.PubMedCentralCrossRefPubMed
41.
42.
Weeke P, Jensen A, Folke F, Gislason GH, Olesen JB, Andersson C, et al. Antidepressant use and risk of out-of-hospital cardiac arrest: a nationwide case-time-control study. Clin Pharmacol Ther. 2012;92:72–9.CrossRefPubMed
43.
Tampi RR, Balderas M, Carter KV, Tampi DJ, Moca M, Knudsen A, et al. Citalopram, QTc prolongation, and torsades de pointes. Psychosomatics. 2015;56:36–43.CrossRefPubMed
44.
Zivin K, Pfeiffer PN, Bohnert ASB, Ganoczy D, Blow FC, Nallamothu BK, et al. Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. Am J Psychiatr. 2013;170:642–50.CrossRefPubMed
45.
Leonard CE, Bilker WB, Newcomb C, Kimmel SE, Hennessy S. Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiol Drug Saf. 2011;20:903–13.PubMedCentralPubMed
46.
Scherrer JF, Garfield LD, Lustman PJ, Hauptman PJ, Chrusciel T, Zeringue A, et al. Antidepressant drug compliance: reduced risk of MI and mortality in depressed patients. Am J Med. 2011;124:318–24.CrossRefPubMed
47.••
Kim JM, Bae KY, Stewart R, Jung BO, Kang HJ, Kim SW, et al. Escitalopram treatment for major depressive disorder following acute coronary syndrome: a 24-week double-blind placebo-controlled trial. J Clin Psychiatry. 2015;76(1):62–8. This is the newest published randomized double blind placebo controlled trial of an antidepressant for treatment of depression after an acute coronary event.CrossRefPubMed
48.
Gottlieb SS, Kop WJ, Thomas SA, Katzen S, Vesely MR, Greenberg N, et al. A double-blind placebo-controlled pilot study of controlled-release paroxetine on depression and quality of life in chronic heart failure. Am Heart J. 2007;153:868–73.CrossRefPubMed
49.••
Schumacher SM, Gao E, Zhu W, Chen X, Chuprun JK, Feldman AM, et al. Paroxetine-mediated GRK2 inhibition reverses cardiac dysfunction and remodeling after myocardial infarction. Sci Transl Med. 2015;7:277ra31. This preclinical study highlights the potentially beneficial pleiotropic effects of paroxetine on cardiac function.CrossRefPubMed
50.
Kim DH, Daskalakis C, Whellan DJ, Whitman IR, Hohmann S, Medvedev S, et al. Safety of selective serotonin reuptake inhibitor in adults undergoing coronary artery bypass grafting. Am J Cardiol. 2009;103:1391–5.CrossRefPubMed
51.
Xiong GL, Jiang W, Clare RM, Shaw LK, Smith PK, O’Connor CM, et al. Safety of selective serotonin reuptake inhibitor use prior to coronary artery bypass grafting. Clin Cardiol. 2010;33:E94–8.CrossRefPubMed
52.
Labos C, Dasgupta K, Nedjar H, Turecki G, Rahme E. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ. 2011;183:1835–43.PubMedCentralCrossRefPubMed
53.
54.
Cochran KA, Cavallari LH, Shapiro NL, Bishop JR. Bleeding incidence with concomitant use of antidepressants and warfarin. Ther Drug Monit. 2011;33:433–8.PubMedCentralCrossRefPubMed
55.
Wallerstedt SM, Gleerup H, Sundstrom A, Stigendal L, Ny L. Risk of clinically relevant bleeding in warfarin-treated patients–influence of SSRI treatment. Pharmacoepidemiol Drug Saf. 2009;18:412–6.CrossRefPubMed
56.
van Melle JP, de Jonge P, Honig A, Schene AH, Kuyper AMG, Crijns HJGM, et al. Effects of antidepressant treatment following myocardial infarction. Br J Psychiatry. 2007;190:460–6.CrossRefPubMed
57.
Honig A, Kuyper AMG, Schene AH, van Melle JP, de Jonge P, Tulner DM, et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosom Med. 2007;69:606–13.CrossRefPubMed
58.
de Jonge P, Honig A, van Melle JP, Schene AH, Kuyper AMG, Tulner D, et al. Nonresponse to treatment for depression following myocardial infarction: association with subsequent cardiac events. Am J Psychiatry. 2007;164:1371–8.CrossRefPubMed
59.
Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, Giardina EGV. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry. 1991;148:512–6.CrossRefPubMed
60.
Lesperance F, Frasure-Smith N, Laliberte MA, White M, Lafontaine S, Calderone A, et al. An open-label study of nefazodone treatment of major depression in patients with congestive heart failure. Can J Psychiatry. 2003;48:695–701.PubMed
61.
Glassman AH, Roose SP, Bigger Jr JT. The safety of tricyclic antidepressants in cardiac patients. Risk-benefit reconsidered. JAMA. 1993;269:2673–5.CrossRefPubMed
62.
Peyre H, Hoertel N, Hatteea H, Limosin F, Dubuc C, Delorme R. Adulthood self-reported cardiovascular risk and ADHD medications: results from the 2004–2005 National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2014;75:181–2.CrossRefPubMed
63.
Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365:1896–904.CrossRefPubMed
64.
Schelleman H, Bilker WB, Strom BL, Kimmel SE, Newcomb C, Guevara JP, et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics. 2011;127:1102–10.PubMedCentralCrossRefPubMed
65.
Taylor CB, Youngblood ME, Catellier D, Veith RC, Carney RM, Burg MM, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry. 2005;62:792–8.CrossRefPubMed
66.
Zuidersma M, Conradi HJ, van Melle JP, Ormel J, de Jonge P. Depression treatment after myocardial infarction and long-tem risk of subsequent cardiovascular events and mortality: a randomized controlled trial. J Psychosom Res. 2013;74:25–30.CrossRefPubMed
67.
Honkola J, Hookana E, Malinen S, Kaikkonen KS, Junttila MJ, Isohanni M, et al. Psychotropic medications and the risk of sudden cardiac death during an acute coronary event. Eur Heart J. 2012;33:745–51.CrossRefPubMed
68.
Rieckmann N, Kronish IM, Shapiro PA, Whang W, Davidson KW. Serotonin reuptake inhibitor use, depression, and long-term outcomes after an acute coronary syndrome: a prospective cohort study. JAMA Intern Med. 2013;173:1150–1.PubMedCentralCrossRefPubMed
69.
Krivoy A, Balicer RD, Feldman B, Hoshen M, Zalsman G, Weizman A, et al. Adherence to antidepressant therapy and mortality rates in ischaemic heart disease: cohort study. Br J Psychiatry. 2015;206:297–301.CrossRefPubMed
70.
Pizzi C, Rutjes AWS, Costa GM, Fontana F, Mezzetti A, Manzoli L. Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol. 2011;107:972–9.CrossRefPubMed
71.
Chung ML, Dekker RL, Lennie TA, Moser DK. Antidepressants do not improve event-free survival in patients with heart failure when depressive symptoms remain. Heart Lung. 2013;42:85–91.PubMedCentralCrossRefPubMed
72.
Tousoulis D, Antoniades C, Drolias A, Stefanadi E, Marinou K, Vasiliadou C, et al. Selective serotonin reuptake inhibitors modify the effect of β-blockers on long-term survival of patients with end-stage heart failure and major depression. J Card Fail. 2008;14:456–64.CrossRefPubMed
73.
Diez-Quevedo C, Lupón J, González B, Urrutia A, Cano L, Cabanes R, et al. Depression, antidepressants, and long-term mortality in heart failure. Int J Cardiol. 2013;167:1217–25.CrossRefPubMed
74.
Katon WJ, Von Korff M, Lin EHB, Simon G, Ludman E, Russo J, et al. The pathways study: a randomized trial of collaborative care in patients with diabetes and depression. Arch Gen Psychiatry. 2004;61:1042–9.CrossRefPubMed
75.
Katon WJ, Lin EHB, Von Korff M, Ciechanowski P, Ludman EJ, Young B, et al. Collaborative care for patients with depression and chronic illnesses. N Engl J Med. 2010;363:2611–20.PubMedCentralCrossRefPubMed
76.
Stewart J, Perkins AJ, Callahan CM. Effect of collaborative care for depression on risk of cardiovascular events: data from the IMPACT randomized controlled trial. Psychosom Med. 2014;76:29–37.PubMedCentralCrossRefPubMed
77.
Rollman BL, Belnap BH, LeMenager MS, Mazumdar S, Houck PR, Counihan PJ, et al. Telephone-delivered collaborative care for treating post-CABG depression: a randomized controlled trial. JAMA. 2009;302:2095–103.PubMedCentralCrossRefPubMed
78.•
Davidson KW, Bigger JT, Burg MM, Carney RM, Chaplin WF, Czajkowski S, et al. Centralized, stepped, patient preference-based treatment for patients with post-acute coronary syndrome depression: CODIACS vanguard randomized controlled trial. JAMA Intern Med. 2013;173:997–1004. This study extends the evidence for the effect of collaborative care of depression in post-ACS patients.PubMedCentralCrossRefPubMed
79.•
Thombs BD, Roseman M, Coyne JC, de Jonge P, Delisle VC, Arthurs E, et al. Does Evidence Support the American Heart Association’s recommendation to screen patients for depression in cardiovascular care? An updated systematic review. PLoS ONE. 2013;8:e52654. This is a useful cautionary analysis of the limitations of the current state of screening, referral and treatment for depression in coronary disease patients.PubMedCentralCrossRefPubMed
80.
Huffman JC, Mastromauro CA, Beach SR, Celano CM, DuBois CM, Healy BC, et al. Collaborative care for depression and anxiety disorders in patients with recent cardiac events: the Management of Sadness and Anxiety in Cardiology (MOSAIC) randomized clinical trial. JAMA Intern Med. 2014;174:927–35.CrossRefPubMed
81.
Scherrer JF, Chrusciel T, Garfield LD, Freedland KE, Carney RM, Hauptman PJ, et al. Treatment-resistant and insufficiently treated depression and all-cause mortality following myocardial infarction. Br J Psychiatry. 2012;200:137–42.CrossRefPubMed
82.
83.
Shapiro PA. Depression treatment and coronary artery disease outcomes: time for reflection. J Psychosom Res. 2013;74:4–5.CrossRefPubMed
Metadata
Title
Management of Depression After Myocardial Infarction
Author
Peter A. Shapiro
Publication date
01-10-2015
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 10/2015
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-015-0634-4

Other articles of this Issue 10/2015

Current Cardiology Reports 10/2015 Go to the issue

Heart Failure (MR Mehra and E Joyce, Section Editors)

Cardiac Resynchronization Therapy Update: Evolving Indications, Expanding Benefit?

Stroke (D Wang, Section Editor)

Changing Contraindications for t-PA in Acute Stroke: Review of 20 Years Since NINDS

Peripheral Vascular Disease (MR Jaff, Section Editor)

Intermittent Claudication due to Peripheral Artery Disease: Best Modern Medical and Endovascular Therapeutic Approaches

Psychological Aspects of Cardiovascular Diseases (A Steptoe, Section Editor)

Emotional Triggering of Cardiac Dysfunction: The Present and Future

Peripheral Vascular Disease (MR Jaff, Section Editor)

Advances in Axial Imaging of Peripheral Vascular Disease

Psychological Aspects of Cardiovascular Diseases (A Steptoe, Section Editor)

Depression in People with Coronary Heart Disease: Prognostic Significance and Mechanisms

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits